Your browser doesn't support javascript.
loading
Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1.
Cheng, Timothy H T; Thompson, Deborah; Painter, Jodie; O'Mara, Tracy; Gorman, Maggie; Martin, Lynn; Palles, Claire; Jones, Angela; Buchanan, Daniel D; Win, Aung Ko; Hopper, John; Jenkins, Mark; Lindor, Noralane M; Newcomb, Polly A; Gallinger, Steve; Conti, David; Schumacher, Fred; Casey, Graham; Giles, Graham G; Pharoah, Paul; Peto, Julian; Cox, Angela; Swerdlow, Anthony; Couch, Fergus; Cunningham, Julie M; Goode, Ellen L; Winham, Stacey J; Lambrechts, Diether; Fasching, Peter; Burwinkel, Barbara; Brenner, Hermann; Brauch, Hiltrud; Chang-Claude, Jenny; Salvesen, Helga B; Kristensen, Vessela; Darabi, Hatef; Li, Jingmei; Liu, Tao; Lindblom, Annika; Hall, Per; de Polanco, Magdalena Echeverry; Sans, Monica; Carracedo, Angel; Castellvi-Bel, Sergi; Rojas-Martinez, Augusto; Aguiar Jnr, Samuel; Teixeira, Manuel R; Dunning, Alison M; Dennis, Joe; Otton, Geoffrey.
Afiliação
  • Cheng TH; Molecular and Population Genetics Laboratory, Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK.
  • Thompson D; Centre for Cancer Genetic Epidemiology, Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK.
  • Painter J; The Molecular Cancer Epidemiology Laboratory, QIMR Berghofer Medical Research Institute, Brisbane 4006, Australia.
  • O'Mara T; The Molecular Cancer Epidemiology Laboratory, QIMR Berghofer Medical Research Institute, Brisbane 4006, Australia.
  • Gorman M; Molecular and Population Genetics Laboratory, Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK.
  • Martin L; Molecular and Population Genetics Laboratory, Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK.
  • Palles C; Molecular and Population Genetics Laboratory, Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK.
  • Jones A; Molecular and Population Genetics Laboratory, Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK.
  • Buchanan DD; Oncogenomics Group, Genetic Epidemiology Laboratory, Department of Pathology, The University of Melbourne, Victoria, Australia.
  • Win AK; Centre for Epidemiology and Biostatistics, The University of Melbourne, Victoria, Australia.
  • Hopper J; Centre for Epidemiology and Biostatistics, The University of Melbourne, Victoria, Australia.
  • Jenkins M; Centre for Epidemiology and Biostatistics, The University of Melbourne, Victoria, Australia.
  • Lindor NM; Centre for Epidemiology and Biostatistics, The University of Melbourne, Victoria, Australia.
  • Newcomb PA; Department of Health Sciences Research, Mayo Clinic, Scottsdale, AZ, USA.
  • Gallinger S; Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Conti D; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada.
  • Schumacher F; Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA.
  • Casey G; Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA.
  • Giles GG; Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA.
  • Pharoah P; Centre for Epidemiology and Biostatistics, The University of Melbourne, Victoria, Australia.
  • Peto J; Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Australia.
  • Cox A; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.
  • Swerdlow A; Centre for Cancer Genetic Epidemiology, Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK.
  • Couch F; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
  • Cunningham JM; London School of Hygiene and Tropical Medicine, London, UK.
  • Goode EL; Sheffield Cancer Research Centre, Department of Oncology, University of Sheffield, Sheffield, UK.
  • Winham SJ; Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, UK and 17 Division of Breast Cancer Research, Institute of Cancer Research, London, UK.
  • Lambrechts D; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Fasching P; Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
  • Burwinkel B; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Brenner H; Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
  • Brauch H; Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
  • Chang-Claude J; Department of Oncology, KU Leuven, Belgium.
  • Salvesen HB; University of California at Los Angeles, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, Los Angeles, CA, USA.
  • Kristensen V; Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
  • Darabi H; Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.
  • Li J; Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology Stuttgart, University of Tuebingen, Germany.
  • Liu T; Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology Stuttgart, University of Tuebingen, Germany.
  • Lindblom A; Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.
  • Hall P; Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology Stuttgart, University of Tuebingen, Germany.
  • de Polanco ME; Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.
  • Sans M; Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.
  • Carracedo A; Department of Clinical Science, Center for Cancer Biomarkers, University of Bergen, Norway.
  • Castellvi-Bel S; Department of Genetics, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo, Norway; The K.G. Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Department of Clinical Molecular Oncology, Division of Medici
  • Rojas-Martinez A; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
  • Aguiar Jnr S; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
  • Teixeira MR; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
  • Dunning AM; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
  • Dennis J; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Otton G; Grupo de investigación Citogenética, Filogenia y Evolución de Poblaciones, Universidad del Tolima, Ibagué, Tolima, Colombia.
Sci Rep ; 5: 17369, 2015 12 01.
Article em En | MEDLINE | ID: mdl-26621817
ABSTRACT
High-risk mutations in several genes predispose to both colorectal cancer (CRC) and endometrial cancer (EC). We therefore hypothesised that some lower-risk genetic variants might also predispose to both CRC and EC. Using CRC and EC genome-wide association series, totalling 13,265 cancer cases and 40,245 controls, we found that the protective allele [G] at one previously-identified CRC polymorphism, rs2736100 near TERT, was associated with EC risk (odds ratio (OR) = 1.08, P = 0.000167); this polymorphism influences the risk of several other cancers. A further CRC polymorphism near TERC also showed evidence of association with EC (OR = 0.92; P = 0.03). Overall, however, there was no good evidence that the set of CRC polymorphisms was associated with EC risk, and neither of two previously-reported EC polymorphisms was associated with CRC risk. A combined analysis revealed one genome-wide significant polymorphism, rs3184504, on chromosome 12q24 (OR = 1.10, P = 7.23 × 10(-9)) with shared effects on CRC and EC risk. This polymorphism, a missense variant in the gene SH2B3, is also associated with haematological and autoimmune disorders, suggesting that it influences cancer risk through the immune response. Another polymorphism, rs12970291 near gene TSHZ1, was associated with both CRC and EC (OR = 1.26, P = 4.82 × 10(-8)), with the alleles showing opposite effects on the risks of the two cancers.
Assuntos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Polimorfismo Genético / Neoplasias Colorretais / Proteínas / Neoplasias do Endométrio / Proteínas de Homeodomínio / Predisposição Genética para Doença / Estudo de Associação Genômica Ampla / Proteínas de Neoplasias Tipo de estudo: Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Female / Humans / Male Idioma: En Revista: Sci Rep Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Polimorfismo Genético / Neoplasias Colorretais / Proteínas / Neoplasias do Endométrio / Proteínas de Homeodomínio / Predisposição Genética para Doença / Estudo de Associação Genômica Ampla / Proteínas de Neoplasias Tipo de estudo: Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Female / Humans / Male Idioma: En Revista: Sci Rep Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Reino Unido